To our knowledge, we discovered for the first time that both bTMB (cutoff level ≥ 6 mutations per Mb) and KRAS mutations were powerful independent bIRPSs that can predict outcomes in Qujing populations with advanced NSCLC from cohort 2 not treated with ICIs. This evidence concerns the gene KRAS and non-small cell lung carcinoma.